Why Eli Lilly Stock Is Plunging Today

Shares of Eli Lilly (NYSE: LLY) were plunging 14.8% as of 11:14 a.m. ET on Thursday. The big drugmaker reported results for the second quarter of 2025 that beat expectations, with soaring sales of type 2 diabetes drug Mounjaro and weight-loss drug Zepbound. So why did Lilly's share price sink like a brick today? The company also announced results from a phase 3 study of its oral GLP-1 agonist, orforglipron, that caused concerns. To be clear, orforglipron didn't flop in its late-stage study. The company said that all three doses of the experimental drug met the primary end point of the trial as well as all key secondary end points. Patients receiving a 36 mg dose of orforglipron once daily experienced an average weight loss of 12.4% (27.3 pounds) versus a weight loss of 0.9% (2.2 pounds) for patients receiving a placebo. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool